Skip to Main content Skip to Navigation
Journal articles

PML hyposumoylation is responsible for the resistance of pancreatic cancer

Abstract : The dismal prognosis of pancreatic ductal adenocarcinoma (PDAC) is mainly due to its rapidly acquired resistance to all conventional treatments. Despite drug-specific mechanisms of resistance, none explains how these cells resist the stress induced by any kind of anticancer treatment. Activation of stress-response pathways relies on the post-translational modifications (PTMs) of involved proteins. Among all PTMs, those mediated by the ubiquitin family of proteins play a central role. Our aim was to identify alterations of ubiquitination, neddylation, and sumoylation associated with the multiresistant phenotype and demonstrate their implications in the survival of PDAC cells undergoing treatment. This approach pointed at an alteration of promyelocytic leukemia (PML) protein sumoylation associated with both gemcitabine and oxaliplatin resistance. We could show that this alteration of PML sumoylation is part of a general mechanism of drug resistance, which in addition involves the abnormal activation of NF-kB and cAMP response element binding pathways. Importantly, using patient-derived tumors and cell lines, we identified a correlation between the levels of PML expression and sumoylation and the sensitivity of tumors to anticancer treatments.-Swayden, M.
Complete list of metadata

Cited literature [46 references]  Display  Hide  Download
Contributor : Philippe Soubeyran Connect in order to contact the contributor
Submitted on : Tuesday, January 14, 2020 - 5:53:41 PM
Last modification on : Wednesday, November 3, 2021 - 4:39:48 AM
Long-term archiving on: : Wednesday, April 15, 2020 - 8:22:42 PM


 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document




Mirna Swayden, George Alzeeb, Rawand Masoud, yolande Berthois, Stéphane Audebert, et al.. PML hyposumoylation is responsible for the resistance of pancreatic cancer. FASEB Journal, Federation of American Society of Experimental Biology, 2019, 33 (11), pp.12447-12463. ⟨10.1096/fj.201901091R⟩. ⟨inserm-02439811⟩



Record views